NEUP Neuphoria Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1191070 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY47.5%
TTM EPS YoY127.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-27.6%
ROA-18.3%
ROIC (approx.)-568.0%
Asset turnover—
Leverage & solvency
Liabilities / assets13.4%
Debt / equity0.00x
Current ratio18.05x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.95x
Accruals ratio17.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2025Q22025-12-31 | 2025Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | -$13,267 | $15.00M | $662,715 |
| R&D expense | — | — | — | $697,723 | $3.79M | $3.75M | $1.62M | $1.74M |
| SG&A expense | $2.10M | $1.76M | $1.69M | $2.13M | $1.87M | $2.07M | $1.41M | $2.63M |
| Operating income | -$2.10M | -$5.53M | -$1.21M | -$4.06M | -$5.65M | -$5.84M | $11.98M | -$3.70M |
| Pretax income | -$1.46M | -$4.94M | -$539,856 | $1.83M | -$9.94M | -$9.15M | $11.18M | -$1.93M |
| Income tax | -$34,793 | -$34,793 | -$34,793 | -$34,794 | -$34,793 | -$266,602 | -$81,186 | $11,609 |
| Net income | -$1.43M | -$4.90M | -$505,063 | $1.86M | -$9.91M | -$8.88M | $11.26M | -$1.94M |
| EBITDA | -$1.93M | -$5.36M | -$1.05M | -$3.90M | -$5.49M | -$5.67M | $12.14M | -$3.54M |
| EPS (basic) | -0.26 | — | -0.09 | 0.41 | -4.41 | — | 6.55 | -1.23 |
| EPS (diluted) | -0.26 | — | -0.09 | -0.77 | -4.41 | — | 6.55 | -1.79 |
| Weighted avg. shares (diluted) | 5.41M | — | 5.41M | 4.54M | 2.25M | — | 1.72M | 1.58M |
| Balance sheet | ||||||||
| Cash & equivalents | $18.74M | $19.87M | $19.44M | $22.17M | $13.65M | $14.29M | $17.04M | $4.34M |
| Receivables | $700,219 | $813,431 | $1.61M | $1.11M | $1,758 | $11,948 | $24,592 | $35,561 |
| Current assets | $19.60M | $21.07M | $21.66M | $23.39M | $13.95M | $15.04M | $17.09M | $4.40M |
| PP&E, net | — | — | — | — | $2,573 | $2,771 | $1,623 | $1,683 |
| Goodwill | $3.53M | $3.50M | $8.84M | $8.74M | $8.67M | $8.64M | $8.45M | $8.41M |
| Intangibles | $3.98M | $4.14M | $4.31M | $4.47M | $4.64M | $4.80M | $4.97M | $5.14M |
| Total assets | $27.11M | $28.71M | $34.81M | $36.60M | $27.34M | $28.59M | $30.71M | $18.17M |
| Current liabilities | $1.09M | $756,581 | $1.51M | $2.59M | $5.12M | $4.22M | $1.55M | $2.13M |
| Total liabilities | $3.63M | $4.11M | $5.39M | $6.90M | $14.83M | $9.59M | $4.72M | $4.42M |
| Shareholders' equity | $23.47M | $24.60M | $29.42M | $29.70M | $12.51M | $19.00M | $26.00M | $13.75M |
| Shares outstanding | 5.41M | 5.41M | 5.38M | 5.38M | 2.36M | 1.98M | 1.85M | 1.63M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.13M | $1.21M | -$3.34M | -$6.44M | -$3.79M | -$3.59M | $11.45M | -$3.36M |
| Financing cash flow | — | $0 | $0 | $14.66M | $3.25M | $704,675 | $1.16M | -$111,562 |
| Depreciation & amortization | $165,683 | $165,679 | $165,695 | $165,789 | $165,792 | $165,625 | $165,431 | $166,121 |
| Stock-based compensation | $74,718 | $76,336 | $70,286 | $93,701 | $111,277 | $98,267 | $19,685 | $19,084 |
Free plan shows the latest 8 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.